Clinical Trial: Anticoagulation Combined With Tocilizumab for Interleukin-6 Receptor Inhibition in Acute Cerebral Venous Thrombosis

U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07801638) titled 'Anticoagulation Combined With Tocilizumab for Interleukin-6 Receptor Inhibition in Acute Cerebral Venous Thrombosis' on Aug. 24.

Brief Summary: This study aims to evaluate the efficacy and safety of tocilizumab, an interleukin-6 (IL-6) receptor antagonist, combined with standard anticoagulant therapy compared with standard anticoagulant therapy alone in patients with acute cerebral venous thrombosis (CVT).

Study Start Date: March 01, 2025

Study Type: INTERVENTIONAL

Condition: Cerebral Venous Thrombosis

Intervention: DRUG: Tocilizumab

Tocilizumab 240 mg will be diluted with 0.9% sodium chloride to a total volume of 100 mL and ...